The last 25 years has seen an impressive growth in the evidence base that supports our management of diabetes. In the 1990s, two major trials dominated: UK Prospective Diabetes Study (UKPDS) in drug-naïve Type 2 diabetes 1 and Diabetes Control and Complications Trial (DCCT) in Type 1 diabetes patients. 2 Both trials reported outcomes that continue to resonate in clinics and guidelines around the world, informing on the critical role of glycaemia in the development of microvascular disease and also indicating much longer-term effects on cardiovascular outcome. 3 These findings generated considerable enthusiasm for the notion that we could find ways to rid ourselves of the crippling burden of vascular complications evident in our patients 30 years ago, a view supported by the statin trials which reported reductions in cardiovascular risk in all diabetes subgroups. 4 The effects of metformin on vascular outcomes, reported in UKPDS, encouraged the development of new drug therapies which might both improve glycaemic control and ameliorate the prevalence of diabetes-associated cardiovascular disease. The thiazolidinediones were marketed as a class that could deliver this promise, but controversy surrounding trial outcomes, increasing reportage of drug-related complications and the dramatic demise of rosiglitazone 5 quickly evaporated such optimism.
Fast forward a few years and the entry of incretins has been associated with what have now become primarily safety trials following the US Food and Drug Administration (FDA) ruling on cardiovascular drug safety. Since 2013, three prospective trials of dipeptidyl peptidase IV (DPPIV) inhibitors have been reported, all demonstrating non-inferiority and therefore cardiovascular safety, but none showing cardiovascular benefit. [6] [7] [8] It felt as if the bubble had burst.
On Thursday 16 September in Stockholm at the 51st Congress of the European Association for the Study of Diabetes (EASD), all this changed once again with the presentation of the results from the EMPA-REG prospective study of the SGLT2 inhibitor, empagliflozin in Type 2 diabetes, simultaneously published in the New England Journal of Medicine. 9 In this trial of more than 7000 subjects, individuals were randomised to either 10 or 25 mg empagliflozin or to placebo in addition to their standard care and followed up for a median period of 3.1 years. The results demonstrated a marginal, but statistically significant superiority for empagliflozin (p = 0.04), but a stunning 38% relative risk reduction in death from cardiovascular causes, a 32% risk reduction in death from any cause and a 35% risk reduction in hospitalisation for heart failure.
The predominant action of the SGLT2 inhibitors is to block glucose uptake in the renal tubule leading to glycosuria and associated reductions in HbA1c, some loss of weight and a small fall in blood pressure. In some quarters, the development of this drug was met with disbelief -after all weren't we just going to reproduce the symptoms of uncontrolled diabetes in our patients? The naysayers, of whom this editor was one, now have good cause to revisit their assumptions.
It is early days and the dust needs to settle on these findings. Important questions arise as to whether this is a class effect or a finding specific to empagliflozin. Perhaps one of the most remarkable observations in a remarkable study is the rapidity with which the lines of effect diverge -hospitalisation for heart failure and death from cardiovascular causes almost immediately. It would be too simple to argue that these two effects are necessarily related in a causal manner, but these findings may help to support the inevitable flurry of studies that will follow trying to explain the outcomes seen in this trial.
This journal was set up a dozen years ago to promote research that investigated the tight biological link between diabetes and vascular disease. In that time, there have been some disappointments and some progress in this field, but nothing to compare with the results of the EMPA-REG trial reported at the EASD. The investigators and sponsors are to be congratulated on a well-designed study with remarkable outcomes that will have major implications for the management of diabetes in the foreseeable future.
Empagliflozin in diabetes:
A therapeutic light at the end of the cardiovascular tunnel?
